GlaxoSmithKline and Innoviva have applied in Europe to market Relvar Ellipta for extended use in patients with asthma who are already adequately controlled on inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) therapy. The treatment, comprised of the ICS fluticasone furoate (FF) and the LABA vilanterol (VI), is currently indicated in Europe for the regular treatment of patients
Advisors to the European Medicines Agency (EMA) have voted in support of approving GlaxoSmithKline/ Theravance’s Relvar Ellipta for both asthma and chronic obstructive pulmonary disease (COPD). The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has delivered a response recommending marketing authorisation for Relvar Ellipta, a combination of the inhaled corticosteroid fluticasone
The National Institute for Health and Clinical Excellence (NICE) have released draft guidance withdrawing their recommendation of Novartis’ Xolair for severe persistent allergic asthma. In 2007, NICE circulated guidelines supporting the use of Xolair (omalizumab) on the National Health Service (NHS) for adults whose asthma is poorly controlled. Then in 2011 they reject the treatment’s
